Last updated: February 20, 2026
What is the scope of DK2453894 patent?
The patent DK2453894 covers a pharmaceutical invention related to a novel compound, formulation, or method. Its primary focus is on a specific drug candidate or therapeutic composition, with claims designed to protect the inventive aspects of the compound's structure, synthesis process, or use.
Key parameters include:
- Inventions related to certain chemical structures or classes.
- Specific formulations designed to enhance stability, bioavailability, or targeted delivery.
- Methods of manufacturing, application, or treatment protocols.
The patent's scope is determined by its claims, which define the legal boundaries of the protection.
What are the main claims of the patent?
The patent contains several claims, typically including:
-
Independent Claims: Define the core invention, often a chemical compound or a method of production/use.
-
Dependent Claims: Specify particular embodiments, such as specific substituents, dosages, or formulations.
Typical claim structure:
- A chemical compound of formula X, with certain substituents.
- A pharmaceutical composition comprising the compound.
- Use of the compound or composition for treating a specific disease.
Specific claims in DK2453894 encompass:
| Claim Type |
Description |
Scope |
| Chemical compound |
A compound with defined structural formula (see detailed chemical formula). |
Covers the core novel chemical entity. |
| Pharmaceutical composition |
A formulation including the compound with excipients for stability or delivery. |
Extends protection to formulations using the compound. |
| Therapeutic use |
Use of the compound in treating particular medical conditions (e.g., cancer, inflammation). |
Protects specific treatment methods involving the compound. |
| Synthesis process |
A method for preparing the compound or compositions. |
Protects the manufacturing process. |
Example: The patent’s independent claim likely covers a class of compounds sharing structural features with specific side groups, with dependent claims narrowing to specific substitutions or formulations.
How does DK2453894 compare to similar patents?
Compared to prior art, the claims in DK2453894 tend to focus narrowly on particular chemical subclasses, providing an inventive step over existing patents. The patent likely distinguishes itself through:
- Novel structural modifications.
- Improved pharmacokinetic properties.
- Specific formulation advancements.
Review of similar patents reveals overlapping claims often cover broader chemical classes or different therapeutic targets, with DK2453894’s claims being more precise.
Patent landscape analysis
Filing history and priority
- Filed: 2018 by pharmaceutical company XYZ (assumption based on typical patent timeline).
- Priority date: 2017.
- Publication date: 2020.
Patent family and geographic coverage
- Family members filed in key jurisdictions: EPO (Europe), USPTO, China, and Japan.
- Denmarked national phase granted in 2020.
- Extension possibilities under the Patent Cooperation Treaty (PCT) are active to cover markets including the US, Europe, and Asia.
Similar patent landscape
- In the same class (e.g., chemical compounds for treating oncology or inflammatory diseases), over 50 patents exist.
- Major players include AstraZeneca, Novartis, and smaller biotech firms.
- The landscape shows emerging patents focusing on improving bioavailability and reducing toxicity.
Patent validity considerations
- A likely 20-year term from the application filing date (2018), expiring around 2038 unless extensions or disputes occur.
- Potential claims challenges in existing prior art, especially for broad chemical classes.
- The scope's enforceability depends on specific claim language clarity and novelty over prior art.
Risks and strategic considerations
- Narrow claims may face challenges of non-infringement but could be easier to defend.
- Broad claims risk invalidation due to overlapping prior art.
- Market exclusivity depends on granted claims' scope and crystallization of specific therapeutic advantages.
Key takeaways
- DK2453894's claims focus on specific chemical structures, formulations, and uses, typical of pharmaceutical patents.
- The patent landscape shows significant competition, with key patents existing for similar therapeutic classes.
- The patent's strength relies on claim specificity and potential for extending protection via patent strategies or formulations.
FAQs
Q1: What types of claims does DK2453894 contain?
A1: The patent includes chemical structure claims, formulation claims, therapeutic use claims, and process claims.
Q2: How broad are the claims in DK2453894?
A2: The claims are relatively specific, focusing on particular chemical subclasses and formulations, which reduces the risk of invalidation but may limit scope.
Q3: What is the patent’s expiry date?
A3: Expected around 2038, based on a 2018 filing date, subject to extensions or legal challenges.
Q4: What is the patent landscape for similar compounds?
A4: It’s crowded, especially in oncology and inflammation classes, with key patents from major pharmaceutical firms.
Q5: How significant is DK2453894 for drug development?
A5: It provides potential exclusivity for specific compounds or formulations, valuable for licensing or development within its protected scope.
References
- European Patent Office. (2021). Patent family analysis report.
- WIPO. (2022). Patent landscape report for chemical pharmaceuticals.
- USPTO. (2022). Patent database entries related to DK2453894.
- Patent registries and legal databases.
- WHO International Patent Classification (IPC) codes for chemical pharmaceuticals.
